- Home
- BIRD vs JSPR Comparison
BIRD vs JSPR Comparison
Compare BIRD & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIRD | JSPR |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1M | 26.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BIRD | JSPR |
|---|---|---|
| Price | $1.94 | $0.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 459.6K | 381.0K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.22 | 19.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $152,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $487.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.05 | $0.32 |
| 52 Week High | $24.31 | $2.42 |
Technical Indicators
Market Signals| Indicator | BIRD | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 31.60 | 47.66 |
| Support Level | N/A | $0.44 |
| Resistance Level | $2.54 | $0.67 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 2.20 | 74.22 |
Price Performance
Historical ComparisonAbout BIRD Allbirds Inc.
Smartbird Inc delivers dedicated AI infrastructure as a service, giving organizations the performance, control, and security of a private AI cluster without requiring them to finance, operate, or maintain the underlying infrastructure. Smartbird manages the entire lifecycle, from procurement and deployment to operations and hardware refreshes, so customers can focus on AI workloads, not AI infrastructure.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.